HRT Access in the United Kingdom: The Complete HRT Guide

Quick Reference Card

Overview / What Is HRT Access in the United Kingdom?

The Basics

Accessing HRT in the United Kingdom is not supposed to mean hunting for a niche private clinic before anyone will listen. In the standard pathway, menopause care begins in primary care: a GP or other NHS prescriber takes a symptom history, checks for contraindications, discusses whether hormone therapy fits the person’s goals and risk profile, and chooses a starting regimen. For many people, that is enough to get treatment started and reviewed on the NHS.[1][3][4]

That is the policy-level picture. The day-to-day reality is messier. Some patients describe quick, confident NHS prescribing. Others describe being told they are “too young,” need unnecessary blood tests, or must wait until they are “fully menopausal,” even though current guidance does not require that in most symptomatic people over 45.[1][3] This gap between what NICE says and what individual practices do is the single most important practical truth about UK HRT access.

Private care sits on top of that system rather than completely outside it. Some people choose private menopause specialists because they want faster appointments, more specialist input, or help with complex cases. In practice, a common UK pattern is private assessment followed by an attempt to have the NHS GP continue prescribing, but that handover is cooperative rather than guaranteed.[8][9]

The Science

The UK access framework is built on a clinical rather than laboratory model. NICE NG23 recommends identifying menopause or perimenopause symptomatically in otherwise healthy people aged 45 or over, without routine hormone testing, and offering HRT for vasomotor symptoms when appropriate.[1] NICE also requires discussion of route, dose, progestogen strategy, duration, and the balance of benefits and risks before starting treatment.[1][2]

Public NHS guidance closely mirrors that framework. NHS menopause pages describe HRT as the main medicine treatment for menopause and perimenopause symptoms, explain that it is safe and effective for most people going through this transition, and direct patients toward 3-month follow-up after starting or changing treatment, followed by yearly review once stable.[3][4] The UK model is therefore not “HRT as last resort,” but “HRT as standard option, individualised to the patient.”

The current access landscape also includes two important practical layers. First, England has a dedicated HRT Prepayment Certificate that can reduce medicine cost for qualifying prescriptions, while Scotland, Wales, and Northern Ireland do not use England’s standard prescription charge structure.[5][13][14][15] Second, supply conditions still change. SPS continues to maintain an HRT availability resource, and BMS says exact product availability can differ between manufacturer reports and what pharmacies can actually obtain.[10][11][12]

Medical / Chemical Identity

A Practical Note

“UK access” is not one single administrative system. Medicine licensing is UK-wide through the MHRA, but prescribing cost and some service design issues differ between England and the devolved nations. A practical access guide therefore has to separate clinical guidance from payment rules.[5][13][14][15]

Mechanism of Action / Pathophysiology

The Basics

The reason HRT access matters is that menopause symptoms are not minor for many people. Estrogen levels become unstable in perimenopause and then fall more persistently after menopause, which can affect temperature regulation, sleep, vaginal and urinary tissues, bone turnover, sexual function, and mood. That is why a person may show up asking about “hot flashes” but also be dealing with insomnia, joint aches, brain fog, anxiety, vaginal dryness, or painful sex.

This physiology is also why a symptom-led UK pathway makes sense. Menopause is not defined by one magic blood result in most people over 45. It is defined by the pattern of symptoms, menstrual change, age, and clinical context. Good access depends on recognizing that reality early, rather than waiting for a laboratory number that often adds confusion rather than clarity.[1][7]

The Science

NICE specifically recommends identifying perimenopause or menopause without laboratory tests in otherwise healthy symptomatic people aged 45 or over, and specifically advises against using AMH, inhibin A/B, estradiol, antral follicle count, or ovarian volume for routine diagnosis in that group.[1] FSRH also states that menopause is usually a clinical diagnosis made retrospectively after a year of amenorrhoea and that most women do not require serum hormone measurements.[7]

These recommendations are not merely administrative shortcuts. They reflect endocrine reality. Hormone levels fluctuate widely during the menopause transition, particularly in perimenopause, and can look “normal” at a single time point despite clinically obvious symptoms. This is one reason many UK access frustrations revolve around inappropriate testing or being told symptoms “do not count” until periods stop completely.[1][7]

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

HRT access in the UK is not access to one medicine. It is access to a menu of routes that change both the physiology and the practical experience of treatment. Estrogen may be prescribed as patches, gels, sprays, tablets, vaginal products, or in some cases other formulations. If the uterus is present, a progestogen strategy also has to be added for endometrial protection, sometimes as a tablet, sometimes as part of a combined product, and sometimes through a 52 mg LNG-IUD.[3][4][6][7]

Route matters because oral and transdermal estrogen do not behave identically. Transdermal therapy avoids first-pass liver metabolism, which is one reason it is often preferred when VTE risk, migraine, gallbladder concerns, triglycerides, or GI absorption issues matter. That route logic shapes UK prescribing choices in both NHS and private settings.[1][11][12]

The Science

NICE requires route-specific risk discussion when HRT is being considered, explicitly naming transdermal versus oral HRT as part of shared decision-making.[1] SPS tells clinicians to use NICE, SmPCs, BNF, BMS resources, and local formulary guidance together when making those route decisions, which reflects how clinically important route selection has become in modern UK menopause care.[11]

SPS availability pages also show that route is not only a pharmacology issue but an access issue. As of late 2025 guidance still in force on 2026-03-26, common UK-available options included estradiol gels, sprays, patches, vaginal estradiol, micronised progesterone, combined oral preparations, combined transdermal patches, tibolone, and prasterone, while some patch products still had active supply issues or recent changes in stock status.[12] In other words, route choice in the UK is partly evidence-driven and partly constrained by what pharmacies can actually source.

Research & Clinical Evidence

HRT for Vasomotor Symptoms and General Menopause Care

The Basics

In UK practice, the core evidence question is no longer whether HRT works for hot flushes and night sweats. It does. The practical question is whether the healthcare professional recognizes the symptom pattern early enough and selects a route and regimen that the patient can actually stay on.

The Science

NICE recommends offering HRT for vasomotor symptoms associated with menopause.[1] NHS public guidance likewise describes HRT as the main medicine treatment for menopause and perimenopause symptoms and says symptom improvement usually depends on choosing the right type and dose.[3][4]

GSM, Vaginal Symptoms, and Local Therapy

The Basics

UK access does not stop at systemic HRT. Many people need local vaginal estrogen even if they do not need systemic therapy, or in addition to systemic therapy. This matters because some patients are denied “HRT” in a whole-body sense when what they really need first is low-dose local vaginal treatment.

The Science

NHS guidance states that a GP can prescribe vaginal estrogen as a tablet, cream, or ring for vaginal dryness and related urinary symptoms, and that it can be used safely alongside HRT.[3] NICE’s 2024 update specifically included revised recommendations on managing genitourinary symptoms associated with menopause, showing how central this area has become in current UK guidance.[2]

Testosterone and Low Sexual Desire

The Basics

Testosterone is the most misunderstood part of UK menopause access. It is not first-line for everyone on HRT. It is a selective option considered when low sexual desire remains distressing despite adequate HRT, and it is much harder to access than standard estrogen and progesterone.

The Science

NICE says to consider testosterone supplementation for people with low sexual desire associated with menopause if HRT alone is not effective.[1] NHS public guidance adds an important legal and practical qualifier: testosterone is not currently licensed for use in women in the UK for this purpose and may be prescribed after menopause by a specialist doctor if they think it might help.[3] That combination explains why the evidence-based answer can still translate into a slower, more specialist-dependent access pathway in practice.

Contraception, Perimenopause, and Endometrial Protection

The Basics

Many UK consultations are not about “post-menopause only” HRT. They are about symptomatic perimenopause in someone who may still bleed, may still need contraception, and still needs clear endometrial protection planning.

The Science

FSRH states that HRT is not contraception, that women using sequential HRT should not rely on it for pregnancy prevention, and that a 52 mg LNG-IUD can be used with estrogen for up to 5 years for endometrial protection as part of an HRT regimen.[7] This is clinically important because it shapes some of the most common real-world UK regimens.

Evidence & Effectiveness Matrix

Categories not scored: Metabolic Health & Insulin Sensitivity, Body Composition & Weight, Joint & Musculoskeletal Health, Skin, Hair & Appearance, Headache & Migraine, Breast Cancer Risk, Endometrial Safety, Other Physical Symptoms

Benefits & Therapeutic Effects

The Basics

The biggest benefit of UK HRT access is not simply “getting a prescription.” It is getting access to licensed, monitored, adjustable treatment through a system that can, at its best, start in ordinary primary care instead of forcing a specialist journey for every patient. For common menopause presentations, that keeps access cheaper, faster, and more sustainable.[1][3][4]

UK access also means route flexibility. A person who does not tolerate tablets may move to gel, patch, or spray. Someone mainly troubled by GSM may use local vaginal estrogen without jumping straight to systemic therapy. Someone with a uterus can use separate progesterone or an LNG-IUD strategy depending on the clinical situation.[3][4][6][7][12]

The Science

NICE and NHS guidance align on HRT’s main therapeutic strengths: vasomotor symptom relief, support for genitourinary symptoms, and bone-health relevance in appropriate patients.[1][3][4] SPS and BMS resources make it clear that the UK system expects treatment to be individualized, not standardized into one “best” product for everyone.[10][11][12]

The access benefit becomes even more important in early menopause, POI, surgical menopause, and other higher-consequence scenarios where under-treatment has broader implications than comfort alone. In those cases, specialist support may be needed, but the principle is still the same: HRT access is part of standard evidence-based care, not a fringe intervention.[1][7][9]

Risks, Side Effects & Safety

The Basics

The clinical risks of HRT in the UK are the same risks that matter anywhere: thrombotic events, stroke, breast cancer considerations, endometrial protection, abnormal bleeding, liver disease, uncontrolled hypertension, and the fact that some people should not use systemic HRT at all. NHS public guidance also highlights pregnancy, liver disease, untreated high blood pressure, clot history, and a history of breast, ovarian, or womb cancer as major suitability issues.[4]

But country access adds a second layer of risk: implementation risk. Wrong product selection, poor follow-up, omission of progestogen, confusing contraception advice, or unplanned switching during a supply disruption can all turn “available HRT” into bad HRT care. UK access is therefore not only about whether a prescriber says yes. It is about whether the route, dose, monitoring, and pharmacy reality stay coherent over time.[1][7][10][12]

The Science

NICE requires explicit benefit-risk discussion before HRT starts and specifically says that transdermal versus oral route, HRT type, progestogen type, sequential versus continuous combined regimens, and dose and duration all matter in that discussion.[1] FSRH reinforces that HRT is not contraception and that sequential HRT must not be relied on for pregnancy prevention.[7]

NHS public guidance explains that low-dose vaginal estrogen acts locally and can be used long term, whereas systemic HRT requires repeated review.[3][4] BMS and SPS add a practical pharmacovigilance layer by steering clinicians toward equivalent licensed alternatives when stock is disrupted rather than leaving patients without treatment.[10][11][12]

Safety conversations work better when symptoms, bleeding, sleep, blood pressure, and side effects are actually tracked instead of remembered vaguely. Doserly helps you log the changes that matter between reviews, so when a clinician asks whether a regimen is helping or harming, you are not stuck trying to reconstruct three months from memory.

That is especially useful in UK practice, where shortages, brand substitutions, and route changes can blur what is a side effect and what is simply a different product. Better tracking makes safer adjustment easier.

Dosing & Treatment Protocols

The Basics

There is no single “UK HRT protocol.” Good UK prescribing usually starts with symptom burden, route preference, risk profile, and uterus status. A common practical starting point is low-dose transdermal or oral estradiol with an appropriate progestogen plan if the uterus is present, then adjustment after early review.[1][3][4]

Some people use fixed-dose combination products. Others use estrogen and progesterone separately. Some use local vaginal estrogen alone. Some use an LNG-IUD for endometrial protection while systemic estrogen is given separately. In practice, UK prescribing has to stay flexible because clinical needs differ and product availability changes.[6][7][10][12]

The Science

NICE requires discussion of combined versus oestrogen-only HRT, route, progestogen type, sequential versus continuous combined HRT, dose, and duration before treatment is started.[1] NHS public guidance says GPs usually start with a low dose and review after about 3 months, adjusting route or dose if symptoms are not controlled or side effects persist.[4]

FSRH adds two important protocol clarifications for perimenopause care: sequential HRT is not contraception, and a 52 mg LNG-IUD may be used with estrogen for up to 5 years for endometrial protection.[7] This is part of why UK menopause prescribing often overlaps with reproductive health expertise more than patients expect.

What to Expect / Timeline

The clinical effect timeline and the access timeline are different, and both matter in the UK.

Access timeline

• NHS primary-care access may be straightforward if the practice is comfortable with menopause care.
• If the practice is not confident, there may be a delay while other causes are ruled out, a second appointment is booked, or referral is considered.
• Private access can be faster, but it introduces consultation fees and does not guarantee NHS continuation afterward.
• Follow-up should usually happen at around 3 months after initiation or change, then yearly when stable.[3][4]

Symptom timeline

• Hot flushes and night sweats may improve within weeks.[3]
• Mood, sleep, libido, and vaginal symptoms may take longer.
• The first prescription is often not the final regimen.
• Persistent bleeding, uncontrolled side effects, or lack of benefit after a fair trial should trigger review rather than indefinite waiting.[1][3][4]

Community discussions repeatedly show that the first successful step is often simply getting the right clinician. Once that happens, the medication timeline usually becomes much more predictable than the access timeline.

Timing Hypothesis / Menopause Window

The Basics

One of the most harmful access myths in UK menopause care is that HRT only “counts” once someone is completely post-menopausal. That is not how current guidance works. Symptomatic perimenopause matters, and UK guidance supports clinical decision-making before the final menstrual period is years in the rear-view mirror.[1][3][7]

The Science

NICE’s diagnostic recommendations clearly allow symptom-led identification of perimenopause in people aged 45 or over who have vasomotor symptoms and menstrual change.[1] NICE’s HRT risk-benefit discussions also remain timing-sensitive, with the most favorable framing generally in those closer to menopause onset and younger than 60, rather than in those starting much later.[1][2]

In access terms, that means the UK system should be addressing symptoms during the transition, not forcing patients to wait until they have endured years of deterioration. The exact regimen may differ in perimenopause, especially when contraception is still needed, but that is a regimen-design issue rather than a reason to deny care.[1][7]

Interactions & Compatibility

UK HRT access involves several compatibility questions that patients often discover too late:

• HRT is not contraception.[7]
• If the uterus is present, estrogen needs compatible endometrial protection.[1][4][7]
• Some people with a history of blood clots may be steered toward patches or gels rather than tablets.[4]
• Uncontrolled hypertension should be addressed before starting HRT.[4]
• Current medicines, herbal products, and liver disease matter when route and formulation are chosen.[4][11]
• The HRT PPC only covers certain licensed menopause medicines, not every prescription someone on HRT might receive.[5][6]

This is one reason UK consultations can feel more detailed than patients expect. A good menopause review is partly a hormone discussion and partly a medication-systems discussion.

Decision-Making Framework

The best UK access decisions usually come from a short set of practical questions:

• Are your symptoms significant enough that you want prescription treatment rather than watchful waiting?
• Are you mainly dealing with whole-body symptoms, GSM, or both?
• Do you still need contraception?
• Do you have a uterus?
• Do clotting history, migraine, blood pressure, liver disease, or cancer history change route choice?
• Is your main barrier clinical complexity, NHS wait time, GP confidence, or medicine cost?
• Do you need a specialist, or do you mainly need a GP willing to follow NICE properly?

For many people, the decision tree looks like this:

1. Start with NHS primary care if a competent GP or prescriber is available.
2. Escalate to a BMS-recognised menopause specialist when the case is complex, repeated regimens have failed, or specialist-only questions such as testosterone or cancer-history management arise.[8][9]
3. Consider private care if access speed or specialist depth matters enough to justify the cost.
4. If private care is used, ask early whether the GP is likely to continue prescribing the plan on the NHS.

Shared decision-making works best when both you and your provider have good data. Doserly gives you a personalized health picture that makes treatment discussions more meaningful — your symptoms, their severity, how they've changed over time, and how they connect to your current protocol.

Whether you're evaluating whether to start HRT, considering a switch to a different route, or discussing whether it's time to adjust your dose, having your own tracked data alongside the clinical evidence puts you in a stronger position to make decisions that reflect your individual experience and goals.

Administration & Practical Guide

NHS route

• Book with a GP, practice nurse, or any clinician in the practice known to handle menopause.
• Bring a symptom list, menstrual-change history, current medicines, and major medical history.
• Ask directly about route options, endometrial protection, contraception, follow-up timing, and what happens if your pharmacy cannot source the product.
• Expect review after around 3 months if treatment starts or changes.[3][4]

Private route

• Use the BMS specialist directory if you want a specialist screen rather than a general internet search.[8]
• Clarify the consultation fee, prescription fee, follow-up expectations, and whether the clinic will write a structured recommendation for your GP.
• Do not assume NHS continuation is automatic; ask whether your GP is willing to prescribe the same plan.

Pharmacy and repeat-prescription reality

• In England, check whether your medicine is actually covered by the HRT PPC before buying one.[5][6]
• If a product is out of stock, ask about equivalent licensed alternatives rather than waiting passively.[10][12]
• If you are in Scotland, Wales, or Northern Ireland, do not assume England cost advice applies.[13][14][15]
• If a repeated stock problem keeps happening, ask the prescriber whether a more consistently available route would be safer and more practical.

Documentation that helps

• Symptom diary
• Bleeding pattern
• Blood pressure readings if relevant
• Pharmacy stock problems or substitutions
• Previous HRT products and why they were stopped

Getting the administration routine right can take some experimenting. Doserly tracks not just whether you took your dose, but when and how — building a picture of your actual routine that can reveal opportunities for optimization.

The app's analytics can show whether small timing shifts affect how you feel, whether your adherence is consistent or has gaps on certain days, and how your routine has evolved since you started treatment. When your provider asks about compliance, you'll have real data — not an estimate — and when something feels off, you can check whether an administration change might be the reason.

Monitoring & Lab Work

Routine estradiol testing is not part of normal UK diagnosis over age 45, and FSRH notes that HRT and CHC suppress hormone measurements in ways that make them unhelpful for standard menopause decision-making.[1][7] Testosterone is different: if it is being considered, specialist-led monitoring is more likely.

Persistent or new vaginal bleeding, uncontrolled side effects, or a pattern of repeated treatment failure should lower the threshold for specialist review rather than endless small tweaks in unsupported primary care.

Complementary Approaches & Lifestyle

HRT access is not the whole of menopause care. UK guidance still expects clinicians to discuss broader health and symptom support:

• bone health and fracture prevention[1]
• physical activity for muscle mass and strength[1]
• CBT for vasomotor symptoms, sleep problems, or mood symptoms when appropriate[2][3]
• vaginal moisturisers or lubricants for GSM alongside or instead of hormonal therapy[3]
• diet, sleep, and exercise strategies that improve the background burden of symptoms

Complementary therapies need caution. NICE and NHS both warn that unregulated preparations and compounded hormone products have uncertain safety and efficacy.[1][3] In UK access terms, that means “private” is not automatically the same thing as “better regulated.”

Stopping HRT / Discontinuation

UK guidance does not support a rigid universal stop date. NICE says treatment duration should be discussed at the outset and rediscussed at every review, and NHS public guidance says people can continue taking HRT for as long as they need it if benefits and risks continue to make sense.[1][3]

Important UK discontinuation realities include:

• symptoms may return after stopping[1]
• treatment can often be restarted if needed[1][3]
• stopping systemic HRT does not always mean stopping vaginal estrogen for GSM[3]
• annual review matters more than arbitrary duration rules

For country access purposes, the key message is that continuing HRT is a review-based decision, not a timer expiring.

Special Populations & Situations

• Breast cancer history: usually specialist-led. NHS public guidance lists a history of breast, ovarian, or womb cancer as a major reason HRT may not be suitable in standard primary care pathways.[4]
• Premature ovarian insufficiency / menopause under 40: requires separate diagnostic and management logic, and specialist input is often appropriate.[1][9]
• Early menopause age 40 to 44: NICE has specific recommendations and updated 2024 attention in this area.[1][2]
• Surgical menopause: often needs more active symptom and bone-health planning than ordinary age-related transition.
• Clotting history or thrombophilia: route choice becomes especially important; transdermal regimens are often more attractive than oral options.[1][4]
• Migraine: route stability matters and may influence the oral-versus-transdermal decision.[1][11]
• Contraception still needed: follow FSRH logic; HRT is not contraceptive, and regimen design must reflect that.[7]
• Complex medical history, repeated failed regimens, or testosterone questions: good reasons to use BMS-recognised specialist pathways.[8][9]
• Trans and gender-diverse patients: menopause guidance and gender-affirming hormone issues overlap in some cases, but not all menopause recommendations map directly onto current gender-affirming hormone use.[1]

Regulatory, Insurance & International

This section is where UK access becomes most concrete.

Regulation and standards

• Medicines are licensed through the MHRA/UK medicines system, while NICE sets the key national clinical guidance used in NHS practice.[1][11]
• Public patient guidance comes from NHS pages, while specialist prescribing support often flows from BMS, FSRH, SmPCs, and SPS resources.[3][4][7][10][11][12]

Payment and coverage

• England: standard NHS prescription charges apply unless the patient is exempt, but the HRT PPC can reduce costs for qualifying medicines. As of 2026-03-26 it costs GBP 19.80 for 12 months.[5]
• Scotland: prescriptions are free.[13]
• Wales: prescriptions written through Welsh NHS arrangements are free, and Wales also has its own pharmacy emergency-medicine arrangements.[14]
• Northern Ireland: NHSBSA’s England guidance FAQ states NHS prescriptions are free of charge in Northern Ireland.[15]

What the HRT PPC does not solve

• It only applies to prescriptions issued in England.[15]
• It only covers certain licensed menopause medicines, not every product someone on HRT might use.[6]
• It does not remove consultation delays, referral waits, or supply shortages.

Supply and substitution

• SPS still treats HRT availability as a live issue and maintains a product-availability resource.[12]
• BMS no longer publishes regular stock updates because manufacturer-level information did not always match wholesale reality, and instead advises checking manufacturers and using equivalent licensed alternatives when needed.[10]

International context

Compared with the United States, the UK offers more centralized guidance and usually lower medicine cost once prescribing is established. Compared with some European systems, UK access can still feel more gatekept because of GP variability and referral bottlenecks. Detailed country-by-country comparisons belong in the other country-access guides rather than being overclaimed here.

FAQ

Do I need a blood test to get HRT in the UK?

Usually not if you are over 45 and have typical menopause-associated symptoms. NICE recommends clinical identification in most of those cases.[1]

Can a GP prescribe HRT in the UK?

Yes. In the standard pathway, a GP or other NHS prescriber is usually the first person who assesses and starts menopause treatment.[3][4]

Do I have to wait until my periods stop completely?

No. Current NICE guidance does not require that in most symptomatic people over 45.[1]

Is HRT free in the UK?

Not under one single rule. Standard NHS prescriptions are free in Scotland, Wales, and Northern Ireland, while England uses prescription charges unless you are exempt.[5][13][14][15]

What is the HRT PPC?

It is an England-only certificate that currently costs GBP 19.80 for 12 months and covers an unlimited number of certain qualifying HRT medicines.[5]

Does the HRT PPC cover every HRT medicine?

No. It only covers certain licensed menopause medicines listed by NHSBSA.[6]

Can I get testosterone on the NHS?

Sometimes, but it is much harder than standard estrogen/progesterone access. NHS public guidance says it may be prescribed by a specialist doctor and it is not licensed for use in women for this indication.[3]

Is private care the only way to get good treatment?

No. Many people are managed successfully on the NHS. Private care is more often an escalation route when expertise, speed, or complexity becomes the problem.[8][9]

Can a private specialist tell my GP what to prescribe?

Yes, that happens in practice, but the GP does not have to accept every private recommendation. Shared care is cooperative, not automatic.

What if my pharmacy cannot get my patch or gel?

Ask the prescriber or pharmacist about equivalent licensed alternatives. SPS and BMS both treat substitution planning as part of normal current practice.[10][12]

Is vaginal estrogen different from systemic HRT?

Yes. Vaginal estrogen mainly treats local GSM symptoms and has a different risk and duration profile from systemic HRT.[2][3]

How often should my treatment be reviewed?

Usually around 3 months after starting or changing HRT, then yearly once stable.[3][4]

Myth vs. Fact

Myth: UK doctors need hormone blood tests before they can diagnose menopause.

Fact: Over age 45, NICE usually recommends symptom-led identification without routine hormone testing.[1]

Myth: You must be fully post-menopausal before UK clinicians can prescribe HRT.

Fact: NICE supports treatment decisions in symptomatic perimenopause as well as after menopause.[1]

Myth: HRT in the UK means tablets only.

Fact: NHS guidance and SPS resources include patches, gels, sprays, tablets, vaginal products, and other licensed options.[3][4][12]

Myth: If you have a uterus, estrogen alone is fine long term.

Fact: Endometrial protection is usually required, whether through progesterone, a combined product, or an LNG-IUD strategy.[1][4][7]

Myth: HRT is contraception.

Fact: It is not. FSRH is clear that sequential HRT should not be relied on for contraception.[7]

Myth: The England HRT PPC covers all menopause medicines.

Fact: It only covers certain licensed HRT medicines listed by NHSBSA.[5][6]

Myth: Private menopause clinics are automatically better regulated than NHS prescribing.

Fact: Regulation and evidence quality depend on the treatment being used. NHS and BMS guidance both warn against unregulated compounded hormone products.[1][3]

Myth: Testosterone is a standard routine part of UK menopause care.

Fact: It is selective, usually specialist-led, and not licensed for use in women for this indication in the UK.[1][3]

Myth: Product shortages mean you should simply stop HRT and wait.

Fact: BMS and SPS both encourage use of equivalent licensed alternatives when exact products are unavailable.[10][12]

Myth: Once you start HRT, there is a fixed time limit and you must stop.

Fact: NICE and NHS guidance support individualized duration with review-based continuation.[1][3]

Sources & References

1. National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Published November 12, 2015. Last updated November 7, 2024. Accessed March 26, 2026.
2. National Institute for Health and Care Excellence. Update information: Menopause: identification and management. Updated November 2024 with May 2025 clarification note. Accessed March 26, 2026.
3. NHS. Menopause - Treatment. NHS website. Accessed March 26, 2026.
4. NHS. About hormone replacement therapy (HRT). NHS website. Accessed March 26, 2026.
5. NHS Business Services Authority. NHS Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC). Accessed March 26, 2026.
6. NHS Business Services Authority. Medicines covered by the Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC). List last updated March 10, 2026. Accessed March 26, 2026.
7. Faculty of Sexual and Reproductive Healthcare. Contraception for Women Aged Over 40 Years. August 2017 guideline, amended May 2025. Accessed March 26, 2026.
8. British Menopause Society. Find a BMS-recognised Menopause Specialist. Accessed March 26, 2026.
9. British Menopause Society. BMS Menopause Specialists Overview. Updated March 12, 2026. Accessed March 26, 2026.
10. British Menopause Society. British Menopause Society update on HRT supply. Published February 25, 2025. Accessed March 26, 2026.
11. Specialist Pharmacy Service. Information resources for advice on HRT. Published June 26, 2024. Accessed March 26, 2026.
12. Specialist Pharmacy Service. Prescribing available HRT products. Updated December 17, 2025. Accessed March 26, 2026.
13. NHS Inform. Prescription charges and exemptions. Updated January 7, 2026. Accessed March 26, 2026.
14. NHS 111 Wales. Services Near You: Pharmacies. Accessed March 26, 2026.
15. NHS Business Services Authority. Can I buy a Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC) if I do not live in England? Accessed March 26, 2026.

Related Guides & Cross-Links

Same Category

• Getting Started with HRT
• Transdermal HRT
• Vaginal Estrogen Therapy
• Compounded & Bioidentical HRT

Related Conditions

• Perimenopause
• Menopause
• Premature Ovarian Insufficiency
• Early Menopause

Related Hormone-Specific Guides

• Micronized Progesterone
• Levonorgestrel IUD
• Testosterone Therapy for Women

Related Country Access Guides

• HRT Access in the United States
• HRT Access in Canada
• HRT Access in Australia
• HRT Access in the European Union